Kexing Biopharm Secures IND Approval for Innovative GB05 in the U.S.#China#Shenzhen#Kexing_Biopharm#GB05#RSV_Treatment
Kexing Biopharm Secures IND Approval for Innovative GB05 in the U.S.
Kexing Biopharm's GB05, an inhalation treatment for RSV, receives IND approval from the FDA, paving the way for clinical trials in the U.S.
third-news.com
February 14, 2025 at 1:13 PM
Kexing Biopharm Secures IND Approval for Innovative GB05 in the U.S.#China#Shenzhen#Kexing_Biopharm#GB05#RSV_Treatment